Aldeyra Therapeutics, Inc.
ALDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001341235
No open-market purchases or sales by Aldeyra Therapeutics, Inc. insiders were filed in the last 90 days; 107 institutions reported holding it in 13F filings for Q2 2026, worth $77.7M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Aldeyra Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 131 | 4 | 136 | +9 |
| Shares | 39.1M | 103.1K | 39.0M | −59.0K (−0.2%) |
| Value | $204.2M | $538.2K | $201.8M | −$1.87M (−0.9%) |
4 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Aldeyra Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| 1492 Capital Management LLC | 223,317 | $1.16M | 0.44% |
| Point72 Asset Management, L.P. | 94,094 | $487.4K | 0.00% |
| Qube Research & Technologies Ltd | 84,928 | $439.9K | 0.00% |
| ACT Capital Management, LLC | 41,000 | $212.4K | 0.17% |
| Canada Pension Plan Investment Board | 35,500 | $183.9K | 0.00% |
| Caption Management, LLC | 35,000 | $181.3K | 0.01% |
| AlphaCentric Advisors LLC | 34,912 | $180.8K | 0.18% |
| Axq Capital, LP | 26,810 | $138.9K | 0.03% |
| Jump Financial, LLC | 24,480 | $126.8K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 23,858 | $123.6K | 0.00% |
| Fox Run Management, L.L.C. | 20,983 | $108.7K | 0.02% |
| Walleye Capital LLC | 18,595 | $96.3K | 0.00% |
| Jones Financial Companies LLLP | 15,000 | $77.7K | 0.00% |
| U.S. Capital Wealth Advisors, LLC | 14,805 | $76.7K | 0.00% |
| SG Americas Securities, LLC | 12,000 | $62.0K | 0.00% |
| Inspirion Wealth Advisors, LLC | 10,000 | $51.8K | 0.01% |
| Global Retirement Partners, LLC | 10,000 | $51.8K | 0.00% |
| UBS Asset Management Americas Inc | 892 | $4.62K | 0.00% |
| MAI Capital Management | 29 | $151 | 0.00% |
| SJS Investment Consulting Inc. | 14 | $73 | 0.00% |
Sold out (11)
Institutions that held Aldeyra Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Marshall Wace, LLP | 160,213 | $836.3K |
| Citadel Advisors LLC | 152,254 | $794.8K |
| Y-Intercept (Hong Kong) Ltd | 138,091 | $720.8K |
| Brighton Jones LLC | 19,945 | $104.1K |
| Quadrature Capital Ltd | 19,275 | $100.5K |
| Inscription Capital, LLC | 12,633 | $65.9K |
| Commonwealth Equity Services, LLC | 10,904 | $57.0K |
| Krilogy Financial LLC | 10,407 | $51.3K |
| New Millennium Group LLC | 2,460 | $12.8K |
| US Bancorp | 554 | $2.89K |
| Sunbelt Securities, Inc. | 2 | $10 |
Not filed for Q4 2025 yet (4)
Institutions that held Aldeyra Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Cubist Systematic Strategies, LLC | 101,375 | $529.2K |
| Point72 Europe (London) LLP | 915 | $4.78K |
| Pineridge Advisors LLC | 600 | $3.13K |
| Point72 (DIFC) Ltd | 213 | $1.11K |